Cellular metabolism, murine pharmacokinetics and preclinical antitumor activity of SN29966, a novel hypoxia-activated pan-HER inhibitor

Patterson, Adam; Jaswail, JK; Syddall, SP; Abbattista, Maria; Van Leeuwen, W; Puryer, MA; Thompson, Aaron; Hsu, A; Mehta, Sunali; Pruijn, A; Lu, Guo-Liang; Donate, F; Denny, William; Wilson, William; Smaill, Jeffrey

dc.contributor.author	Patterson, Adam	en
dc.contributor.author	Jaswail, JK	en
dc.contributor.author	Syddall, SP	en
dc.contributor.author	Abbattista, Maria	en
dc.contributor.author	Van Leeuwen, W	en
dc.contributor.author	Puryer, MA	en
dc.contributor.author	Thompson, Aaron	en
dc.contributor.author	Hsu, A	en
dc.contributor.author	Mehta, Sunali	en
dc.contributor.author	Pruijn, A	en
dc.contributor.author	Lu, Guo-Liang	en
dc.contributor.author	Donate, F	en
dc.contributor.author	Denny, William	en
dc.contributor.author	Wilson, William	en
dc.contributor.author	Smaill, Jeffrey	en
dc.coverage.spatial	Boston, MA, USA	en
dc.date.accessioned	2012-06-12T00:54:31Z	en
dc.date.issued	2009	en
dc.identifier.citation	AACR NCI EORTC International Conference, Boston, MA, 15 Nov 2009 - 19 Nov 2009. Molecular Cancer Therapeutics. 8: B76. 2009	en
dc.identifier.issn	1535-7163	en
dc.identifier.uri	http://hdl.handle.net/2292/18932	en
dc.description.abstract	Hypoxia occurs in most human tumors and is associated with diseaseprogression, resistance to conventional therapies and poor patientoutcome. Hypoxia can up-regulate HER1 by several known mechanisms,including increased mRNA translation (Franovic et al., PNAS,2007;104:13092)and delayed receptor endocytosis (Wang et al., Nat Med.,2009;15:319)	en
dc.relation.ispartof	AACR NCI EORTC International Conference	en
dc.relation.ispartofseries	Molecular Cancer Therapeutics	en
dc.rights	Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.	en
dc.rights.uri	https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm	en
dc.title	Cellular metabolism, murine pharmacokinetics and preclinical antitumor activity of SN29966, a novel hypoxia-activated pan-HER inhibitor	en
dc.type	Conference Item	en
dc.identifier.doi	10.1158/1535-7163.TARG-09-B76	en
pubs.issue	12, supp1 1	en
pubs.begin-page	B76	en
pubs.volume	8	en
dc.rights.holder	Copyright: The American Association for Cancer Research	en
pubs.author-url	http://mct.aacrjournals.org/cgi/content/meeting_abstract/8/12_MeetingAbstracts/B76	en
pubs.finish-date	2009-11-19	en
pubs.start-date	2009-11-15	en
dc.rights.accessrights	http://purl.org/eprint/accessRights/RestrictedAccess	en
pubs.subtype	Abstract	en
pubs.elements-id	298017	en
pubs.org-id	Medical and Health Sciences	en
pubs.org-id	Medical Sciences	en
pubs.org-id	Auckland Cancer Research	en
pubs.org-id	Science	en
pubs.org-id	Science Research	en
pubs.org-id	Maurice Wilkins Centre (2010-2014)	en
pubs.record-created-at-source-date	2012-02-19	en